Thursday, June 11, 2026
Google search engine
Home Blog Page 477

Luye Pharma’s Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao

0

Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer

HONG KONG and MACAO, March 7, 2024 /PRNewswire/ — A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye Pharma Group (Luye Pharma) took place in Hong Kong yesterday. At the conference, Luye Pharma announced the launch of its innovative drug Zepzelca® (lurbinectedin) for the treatment of SCLC in both Hong Kong and Macao, the two Special Administrative Regions of China.

The launch ceremony of Zepzelca®(lurbinectedin)
The launch ceremony of Zepzelca®(lurbinectedin)

Lurbinectedin is a new chemical entity with a novel mechanism of action. It was approved for launch in Macao in November 2023 and in Hong Kong in December 2023 for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. The drug was also approved by the U.S. Food and Drug Administration (FDA) through the accelerated approval process in 2020. For 27 years, it has been the only new chemical entity approved by the U.S. FDA for the treatment of relapsed SCLC since 1997.

Lurbinectedin has overcome a bottleneck in the second-line treatments of SCLC 

SCLC is one of the most aggressive lung cancers, with a five-year survival rate of only 7%[1]. Most patients would experience a relapse or develop drug resistance after the initial treatment, with an mOS (median Overall Survival) of only 4 to 5 months after receiving further chemotherapy[2].

“SCLC is one of the most malignant and highly recurrent subtypes of lung cancer, and for over 20 years, there has been no substantial progress in developing second-line treatments for the disease after a relapse and in improving patient survival,” said Dr. Herbert Loong, an Associate Professor from the Department of Clinical Oncology at the Chinese University of Hong Kong and a council member of HKCTS, who chaired the symposium. “Different from traditional chemotherapy, lurbinectedin is a selective inhibitor of oncogenic transcription with notable activity in SCLC. We believe it can become a new standard second-line treatment for SCLC and help improve patient survival.”

Promising results for Chinese patients in a clinical study

The approval of lurbinectedin in countries and regions including the U.S., Hong Kong and Macao is mainly based on an open-label, multicenter and single-arm study (a Phase 2 basket trial) in 105 adult patients with SCLC (including both platinum-sensitive and platinum-resistant patients) who experienced disease progression after receiving platinum-based chemotherapy. In this trial, they were treated with lurbinectedin alone by receiving 1-hour intravenous infusion of the drug every 3 weeks at a dose of 3.2mg/m2. The study was published in The Lancet Oncology[3]. It demonstrated an ORR (Overall Response Rate) of 35.2%, an mDoR (median Duration of Response) of 5.3 months, and an mOS of 9.3 months for all patients treated with lurbinectedin[3].

“Lurbinectedin was found to be superior to current standard treatments based on their historical data in terms of anticancer activity and safety, and it was effective in both platinum-sensitive and platinum-resistant SCLC patients,” said Dr. Antonio Calles, a specialist from the Department of Medical Oncology at Hospital General Universitario Gregorio Marañón in Madrid, Spain. “In addition to being used as a monotherapy, lurbinectedin is also expected to be used in combination with chemotherapy, immunotherapy or other therapies, to allow SCLC patients to benefit more from it.”

A single-arm, Phase 1 clinical study with dose escalation and expansion for lurbinectedin was conducted, to evaluate its safety, tolerability, pharmacokinetics (PK) and preliminary efficacy in Chinese patients with advanced solid tumors, including recurrent SCLC. The study showed an ORR of 45.5%, an mDoR of 4.2 months, and an mOS of 11.0 months for SCLC patients treated with lurbinectedin (at the FDA-approved dose of 3.2 mg/m2 via 1-hour intravenous infusion every 3 weeks).

At the symposium, Professor Sheng Ye, Director of Clinical Oncology at the First Hospital of Sun Yat-sen University, said: “This study was designed to evaluate the preliminary efficacy and safety of lurbinectedin in Chinese patients. We are excited to see that the performance of lurbinectedin at the FDA-approved dose in Chinese patients with relapsed SCLC whose condition has progressed after receiving a first-line platinum-based chemotherapy is comparable to or even better than its performance in the SCLC cohort of an overseas Phase 2 basket trial in terms of efficacy and patient survival. Lurbinectedin is expected to become a new treatment option of value for Chinese SCLC patients.”

Helping to make innovative drugs more accessible for patients

To date, lurbinectedin has been approved for launch in 16 countries and regions worldwide. Luye Pharma has been granted the rights to develop and commercialize lurbinectedin in Chinese mainland, Hong Kong, and Macao, to allow Chinese patients to benefit from the innovative therapy as soon as possible. In addition to being approved for launch in Hong Kong and Macao, the drug is also under review for its New Drug Application (NDA) in Chinese mainland with a priority review designation.

Andy Siow, APAC VP of Luye Pharma (International), said: “After more than two decades, there is finally a significant advancement in addressing the relapsed SCLC, offering patients the long-awaited hope and clinically improved outcomes. With the introduction of Zepzelca in Hong Kong and Macao, we are actively collaborating with various stakeholders to enhance its accessibility to all patients. Our objective is to expedite patient access to the medication, enhancing their survival prospects and alleviating treatment burdens.

About Zepzelca®(lurbinectedin)

Zepzelca (lurbinectedin) is an analog of the marine compound ET-736 isolated from sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin also presents a marked effect on tumor microenvironment by inhibiting transcription and secretion of selected cytokines by tumor-associated macrophages.

Lurbinectedin has been recommended by multiple clinical guidelines. For instance, it has been recommended as a preferred option in subsequent systemic treatment for SCLC patients with a chemotherapy-free interval (CTFI)≤6 months by the NCCN Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (2024.V2)[4], and has been also recommended for the treatment of relapsed SCLC by the Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[5] (published in 2021) and the CSCO Guidelines for the Diagnosis and Treatment of Small Cell Lung Cancer 2023 [2].

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has also achieved multiple innovations in new chemical entities and antibodies, and is actively making strategic developments in the fields of cell therapies and gene therapies.

Luye Pharma is developing a global supply chain of 8 manufacturing sites built up around the world, with GMP quality management and control systems established in line with international standards. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets – China, the U.S., Europe and Japan, as well as in fast growing emerging markets.

Source

The first over-the-counter continuous glucose monitor just got cleared by the FDA. Here’s what it does — and why monitors like these are popular with nondiabetics too.

0
A young man outdoors stretching his leg on a bench wears a continuous glucose monitor on his upper arm.

What you need to know about continuous glucose monitors following the FDA’s approval of the first over-the-counter device. (Getty Images)

Continuous glucose monitors (CGM) are about to become more accessible, as the Food and Drug Administration announced clearing the first over-the-counter device on March 5. The Dexcom Stelo Glucose Biosensor System will be available this summer and is intended for anyone 18 years and older who does not use insulin. This would include individuals with diabetes using oral medications to treat their condition, as well as people without diabetes who are looking to better understand how diet and exercise may impact blood sugar levels, according to the FDA’s statement. The agency does note that the nonprescription CGM should not be used by people with “problematic hypoglycemia,” also known as low blood sugar, “as the system is not designed to alert the user to this potentially dangerous condition.”

Given the increased access to these monitors and the growing trend of people who don’t have diabetes using them as “personal health devices” to monitor how foods impact their blood sugar levels and to motivate themselves to make healthy behavioral changes, it’s important to understand what a CGM is and who really needs one. Here’s everything you need to know.

🩸 What is a continuous glucose monitor?

It’s a wearable technology that allows you to track blood sugar levels 24 hours a day, without having to prick your finger for a blood test. The device is worn on either the arm or the abdomen, where a small sensor is inserted just under the skin. The sensor measures glucose levels and wirelessly transmits the data to a device, via a downloadable app, for viewing.

🔬 What information does it provide?

CGMs provide continuous information on glucose levels, allowing a user to see what their current numbers are at any moment, while also getting insight into trends, such as foods, physical activities, stressors or illnesses that may cause a spike. The alternative is using a finger-stick blood test, which provides data for only a point in time. “You don’t know if that number is going up or going down or holding steady,” Dr. Michael Natter, an endocrinologist at NYU Langone Health and a type 1 diabetic, tells Yahoo Life. The goal is to keep blood sugars within a certain range, as levels too high or too low can damage organs and lead to potentially life-threatening complications. For diabetics, this often requires management through insulin therapy.

🤷‍♀️ Who needs to use a CGM?

These devices are made primarily for those living with type 1 or type 2 diabetes who are managing their condition with insulin. However, Dexcom reports that there are approximately 25 million people in the U.S. living with type 2 diabetes who do not use insulin and can still benefit from CGM technology.

ADVERTISEMENT

Advertisement

According to Cleveland Clinic, the wearable device can provide several benefits, such as:

  • Showing a more complete picture of how blood sugar levels change over time.

  • Pinpointing any patterns in blood sugar changes so physicians can create a personalized plan for patients.

  • Warning about blood sugar that is too high or too low.

  • Reducing the number of finger-stick tests patients need to do, although they may still be required for diabetes management.

Natter points out that there’s also a population of diabetics who haven’t had access to a CGM because of different scenarios where insurance is unwilling to cover the cost of the device. Although the price of the over-the-counter device isn’t yet available, he says that population would “benefit from access to affordable nonprescription” CGMs.

💪 Why would a nondiabetic use it?

These monitors are the latest tool in biohacking — the trending practice of using medical methods to boost physical or mental performance, enhance health and well-being, or reach specific health goals. And while they’ve gained popularity among certain fitness fanatics and wellness gurus, experts have tried to figure out why.

ADVERTISEMENT

Advertisement

Dr. Robert Shmerling of Harvard Health identified some possible reasons, such as potentially identifying prediabetes, “optimizing” blood sugar for “peak mental or physical performance,” the “illusion” of feeling more in control of their health, and simple curiosity.

However, there’s little research published to solidify any potential benefits of wearing a CGM as a nondiabetic. Some experts, including Natter, are skeptical. “I think there are downsides to having too much data. Because while these continuous glucose monitors are wonderful and relatively accurate, they are not meant to pick up very subtle glucose swings. And when we see a small spike after a meal, that could actually be very normal,” he says. “I fear that might be overinterpreted and misread as pathologic or bad.” Natter says that he’s also wary of foods becoming “demonized” because of resulting blood sugar spikes.

🤔 The main takeaway

While Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, tells Yahoo Life that “giving more individuals valuable information about their health, regardless of their access to a doctor or health insurance, is an important step forward in advancing health equity for U.S. patients,” some physicians are hesitant about individuals monitoring their medical data on a nonprescription device.

“It gets a little bit nuanced,” says Natter. “If there’s someone taking medication and monitoring with any device, I think it’s safest to have a medical professional shepherding that patient through.”

Source

WEPACK 2024 will present much-expected kaleidoscopic highlights this April

0

SHENZHEN, China, March 7, 2024 /PRNewswire/ — As part and parcel of the industrial manufacturing industry, the packaging industry is accelerating transformation and development, with continuous emergence of relevant new industries, business formats, technologies and models bringing new opportunities for further cross-border integration, industrial chain ecologization, and automated intelligence development in the industry.

WEPACK 2024 will be held from April.10-12 at the Shenzhen World Exhibition & Convention Center (Bao'an New Hall), China
WEPACK 2024 will be held from April.10-12 at the Shenzhen World Exhibition & Convention Center (Bao’an New Hall), China

Based on excellent specialization, marketization and internationalization, WEPACK organized by RX has already become an international window for cutting-edge information exchange in the global packaging industry and provided the Chinese packaging industry with a platform to link to the world and showcase its strength over the years.

To be held at Shenzhen World Exhibition & Convention Center from April 10 to 12, 2024, WEPACK 2024 will feature six concurrent shows, including: SinoCorrugated South 2024, SinoFoldingCarton 2024, PACKCON 2024, DPrint 2024, SinoPaper South 2024, and Food Pack & Tech 2024. It will compose the charm of the packaging industry in a new posture, create a carrier-class grand show in the international packaging industry characterized by a larger scale, higher influence, wider coverage and richer exhibit categories, and pool together 1,200+ exhibitors, with an estimate of 100,000+ global packaging industry personnel attracted to the venue.

•    120,000 m2 of exhibition area
•    50,000+ cardboard and carton manufacturing enterprises
•    30,000+ folding carton color printing manufacturing enterprises
•    10,000+ label and flexible packaging manufacturing enterprises
•    1,000+ graphic express printing enterprises
•    20,000+ packaging R&D and purchasing personnel of brand owners
•    1,000+ raw paper distributors
•    3,000+ food & catering packaging enterprises
•    6,000+ overseas paper packaging enterprises (from 110 countries and regions)
•    3,000+ representatives from overseas regions
•    50+ hot trend forums + events of the packaging industry

WEPACK 2024 floor plan at the Shenzhen World Exhibition & Convention Center (Bao'an New Hall)
WEPACK 2024 floor plan at the Shenzhen World Exhibition & Convention Center (Bao’an New Hall)

Six concurrent exhibitions, build a collaborative development pattern across the whole packaging industrial chain
No success could be achieved in a single field without considering the bigger picture. In the current era, the economic development blueprint of “the industrial chain as a whole” is being sketched out. A key driver of the packaging industry’s high-quality development, WEPACK 2024, based on over twenty years of industry accumulation, moves faster to integrate into the global packaging industrial chain. With an exhibition area of 120,000 m2, this edition has incorporated 6 major sectors of packaging series exhibitions. By that time, carton processing equipment and materials, folding carton processing equipment and materials, digital label printing equipment and materials, packaging container manufacturers, raw paper manufacturers, and catering packaging processing equipment enterprises and material suppliers will jointly manifest the new high ground of packaging intelligent manufacturing.

  • SinoCorrugated South 2024
    SinoCorrugated South is not only a “grand stage” for carton manufacturing, but also an irreplaceable trading and exchange platform in the global carton industry. Outstanding exhibitors from various segments will come in droves to SinoCorrugated South 2024, showcasing their star products and delivering rich, diverse, and cutting-edge corrugated box processing solutions to the industry.
  • SinoFoldingCarton 2024
    A specialized exhibition for folding carton printing and post-press processing equipment, consumables, technologies, and services, SinoFoldingCarton 2024 pools more than 400 renowned brands from home and abroad. Exhibiting over 500 high-end and cost-effective devices, and more than a thousand types of consumables under one roof, it serves as a preferred platform for purchasing folding carton processing equipment and gaining information about new industry trends.
  • DPrint 2024
    Focused on digital application equipment and technologies of whole-category packaging products printing and forming, DPrint 2024 is the only exhibition in China that spotlights digital printing solutions in the packaging industry. Previous editions of the exhibition pooled together hundreds of well-known supplier brands from home and abroad to showcase currently advanced printing and forming digital application technologies for labels, cartons, folding cartons, flexible packaging, metals, etc. together, as well as high-end and cost-effective equipment and consumables, so as to drive the development and application of digital printing technologies. 
  • SinoPaper South 2024
    SinoPaper South 2024 will comprehensively demonstrate three major categories: packaging paper, commercial printing paper, and special paper, and pool resources from numerous overseas paper mills, so as to enrich raw paper purchase channels for enterprises with paper demands and lower production costs. The “raw paper trade purchase zone” to be set up at the exhibition will provide more quality raw paper purchase options for paper packaging enterprises in the Greater Bay Area of South China.
  • Food PACK & TECH 2024
    Specializing in the food contactable packaging field, FOOD PACK & TECH 2024 covers the whole process of manufacturing, processing, forming and detection, etc. for finished packaging products. Committed to creating uniqueness and concreteness within the packaging industry, it serves as a one-stop specialized trade platform showcasing leading food packaging product processing equipment and technologies, as well as food-grade packaging materials.
  • PACKCON 2024
    Jointly organised by the China Packaging Federation and RX, PACKCON is a platform for sourcing and exchanging all types of packaging and containers, combining on-site exhibitions, conferences, events, live courses, business matching and other professional services, and bringing together more than 30,000 packaging purchasing decision makers from the eight end-user fields, and it is the perfect platform for packaging and containers suppliers to learn about the market information, get high-quality orders, and build up business contacts.

With increasing internationalization, global industry associations, agencies, and trade visitors convene in Shenzhen

Based on its ongoing dive in the domestic packaging industry, the organizer RX actively grasps overseas incremental markets, taps into emerging market regions, pools global purchase power, and assists suppliers of equipment and consumables in the packaging industry in expanding global trade, precisely opening up dual tracks of both domestic and overseas markets, and achieving dual value added in branding and profits.

Domestically, an estimate of 50,000+ cardboard and carton manufacturing enterprises, 30,000+ folding carton and color printing manufacturing enterprises, 10,000+ label and flexible packaging manufacturing enterprises, and 20,000+ packaging R&D and purchasing personnel of brand owners will visit the site.

Internationally, RX possesses 600,000 carton enterprise databases at home and abroad covering foreign and domestic target customers. They are upgraded in a timely manner to strictly ensure up-to-date data. Trade buyers and regional agencies will be selected from such databases for onsite visit and consultation.

It is foreseeable that packaging industrial chain enterprises at home and abroad will gather in Shenzhen from April 10 to 12, joining hands to draw the blueprint for the global packaging industry development.

50+ concurrent events bring together global packaging industry big shots, with excitements staged one after another

Apart from a complete array of exhibits in the packaging industry chain, the exhibition will concurrently host a series of high-standard forums, and invite representatives from domestic and international packaging industry associations, authoritative institutions, renowned enterprises in the industry, and industry leaders to the site. These forums will focus on hot topics of common interest in the packaging industry to unfold substantiated academic feasts and brainstorms one after another, where continuous excitements will maximize the experience feeling of both exhibitors and visitors.

In the past 20-odd years, the organizer of WEPACK, along with domestic and international packaging enterprises, associations, institutions, media, and numerous personnel who care about the industry’s development, experienced the transformation era in the packaging industry together, and witnessed and accomplished today’s new landscape in the packaging industry. In the future, WEPACK will maintain an open, collaborative, and innovative stance, assume the task of driving packaging industry development, grow and progress together with the industry, jointly build a grand platform for market development, and usher in a new era for the global packaging industry!

April 10th-12th let’s meet at the Shenzhen World Exhibition & Convention Center (Bao’an New Hall)!

CONTACT: Oliver Zhang, oliver.zhang@rxglobal.com

Source: RX (China) Investment Co., Ltd.

Source

Newborn Town Gains YoY Increase of over 280% in Profit Attributable to Owners as MENA Market and New Products Become Key Growth Drivers

0

HONG KONG, March 6, 2024 /PRNewswire/ — Newborn Town Inc. (“Newborn Town”; 9911. HK) released its positive profit alert for the year ended 31 December on 5 March. The company has continued its growth momentum and achieved a remarkable increase in major indicators.

Newborn Town’s total revenue for 2023 is expected to be approximately RMB3,270 million to RMB3,410 million, representing a YoY increase of 17% to 22%. The net profit will see a YoY rise of 161% to 182%, as it’s expected to be around RMB750 million to RMB810 million.

The profit attributable to the owners of Newborn Town will reach RMB500 million to RMB560 million, increasing by 285% to 331%. The adjusted EBITDA will be around RMB670 million to RMB730 million, representing an increase of around 79% to 95% compared to the corresponding period in 2022.

Newborn Town is the tech company that eyes global social networking and entertainment markets
Newborn Town is the tech company that eyes global social networking and entertainment markets

According to the announcement, Newborn Town’s profit growth has been achieved due to the progress made in the social networking business, especially in MENA and new social apps.

The past year has witnessed continued rapid breakthroughs in major markets like MENA and remarkable progress in the scale-up and commercialization of ‘second-mover’ apps like SUGO and TopTop, enhancing Newborn Town’s overall businesses’ high-quality growth.

MICO, YoHo, SUGO and TopTop, the flagship apps under Newborn Town’s ‘pan-audience social networking business’, aim to meet global users’ diversified social demands.

Most social apps in this segment have made rapid strides as they’ve evolved into top-notch platforms in emerging markets like MENA and SEA.

Based on the localized capabilities accumulated in the long-term process of globalization, Newborn Town has fully implemented the ‘replication’ strategy, enhancing the rapid scale-up of new products in target markets while lowering operational costs and upgrading commercialization efficiency.

For example, the companion-based social app SUGO showed a surge in revenue and profit in 2023, representing a triple YoY increase. Besides, it has been ranked among the top 30 Chinese non-game publishers in terms of overseas revenue released by data.ai many times.

Newborn Town has also accelerated its exploration of the ‘diverse-audience social networking business’ and gained ground. In 2023, the company completed the acquisition of BlueCity and achieved profitability.

On 1 January 2024, Newborn Town officially unveiled the online community app HeeSay to over 70 countries and regions worldwide. Based on the user base and brand influence that the international version of Blued has accumulated previously, HeeSay has revved up its global business layouts with the advantages of deep localization.

It’s noteworthy that HeeSay has achieved sustained profitability since its closed beta test. Henceforth, the boundary of Newborn Town’s social networking business won a further expansion while its commercialization efficiency got continuous upgrades.

Apart from the above-mentioned segment, Newborn Town’s innovative business has achieved breakthroughs in 2023. The flagship game, Alice’s Dream: Merge Island, witnessed a continued rise in monthly revenue, reaching over 8 million US dollars in the fourth quarter of 2023.

Besides, Alice’s Dream was also a top-ranked frequenter in Sensor Tower’s lists regarding overseas revenue and downloads this year.

In addition to the success of Alice’s Dream, Newborn Town rolled out new apps like Taylor’s Secret, Merge Cove, and Sudoku to capture a larger global market share of puzzle games.

Notably, according to data.ai, Sudoku ranked third on the US mid-core casual games list for June 2023.

In 2023, Newborn Town took the ‘pan-audience social networking business’ as its core segment and achieved further breakthroughs among key markets while verifying the growth potential of newly launched products.

Meanwhile, the diverse-audience social networking business and the game-centric innovative business have progressed smoothly, jointly promoting the high-quality growth of Newborn Town.

Newborn Town will continue to increase its input and dig deep into vast opportunities in MENA while focusing on diverse-audience social networking and quality games to gain diversified and sustainable growth in the years to come.

It’s reported that Newborn Town will hold the annual results announcement in Hong Kong on March 22, 2024.

Source

Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina’s Growth Vision

0

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors

MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ — Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment of Mark W. Womack as a Director of the Board.

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors
Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors

“We are thrilled to have Mark join the Board, as a Director of the Company,” said Dr. Masood Tayebi, Co-Founder and Chief Executive Officer of Bridgewest Group. “Mark has demonstrated his skills as both an entrepreneur and a visionary with multiple highly successful organizations, and we are excited to have his advice and wisdom at the Board level for Bridgewest Perth Pharma broadly, and more specifically NovaCina’s commercial manufacturing of sterile injectables.”

Mark currently serves as CEO of BioCina, a Bridgewest Group funded CDMO providing end-to-end biologics solutions for microbial, pDNA and mRNA modalities globally. Prior to BioCina, as CEO of KBI Biopharma and Selexis SA, he spearheaded a run rate of over 30% YOY revenue increase in only 6 months and implemented a new commercial strategy to generate significantly greater client program size and profitability. As CEO and Managing Director of Stelis Biopharma, Mark ushered efforts to build and qualify a state-of-the-art vaccine facility in record time.

As the CBO for AGC Biologics, one of the world’s leading global biopharma CDMO’s, Mark led the organization to achieve nearly a 300% increase in new sales in just two years. Over two years, he drove the acquisition of many of the top large pharma companies into the AGC Biologics Client portfolio.

Prior to joining AGC Biologics, Mark served over 20 years as a management consulting industry leader and C-level client advisor, guiding many of the world’s renowned companies to achieve record highs in revenue and profit. He served as a Principal with Capgemini, an EVP with Celerant Consulting and as COO of two other international consultancies. While at Capgemini, he led a $20B post-merger integration within General Motors.

“This is a tremendous opportunity to help guide and shape the future of the NovaCina and LumaCina organizations. I’m inspired by the vision we share and excited about the journey we will travel to realize it,” said Mark W. Womack.

In April 2023, Bridgewest Group announced the acquisition of the Pfizer Perth cGMP sterile injectable manufacturing plant, and the formation of Bridgewest Perth Pharma, including the NovaCina CDMO division and LumaCina pharmaceutical supply division. NovaCina has a preeminent history. The site has produced more than 600 injectable products with distribution to nearly a hundred countries globally, and has an excellent track record spanning all major regulatory approvals including US FDA, TGA, and European regulatory agencies.  Since the acquisition, the company has invested significantly into both NovaCina and LumaCina. It has grown NovaCina’s manufacturing capabilities to include Pre-filled Syringes (PFS) and has expanded LumaCina’s product catalog, growing its commercial reach into several new global markets.

About Bridgewest Perth Pharma
Bridgewest Perth Pharma is a global pharmaceutical company, wholly owned by private investment firm Bridgewest Group. It operates through its two divisions, NovaCina, the company’s CDMO, and LumaCina, the company’s pharmaceutical marketing and supply division. Bridgewest Perth Pharma brings together innovative life sciences and talented people to meet the escalating demand for high quality drug manufacturing and therapeutics. For more information, visit: https://bridgewestperthpharma.com.au/

Media Contact: Jenny Bourbiel, jbourbiel@bridgewestgroup.com

Source

Is dairy harder to digest as you get older? Nutritionists address the biggest misconceptions about milk.

0

Alternative milks, such as oat and almond, have surged in popularity, while cow’s milk sales in the U.S. have been on the decline for years. While there are several reasons behind dairy’s drop in popularity and why many people are seeking alternatives, including lactose intolerance, some are questioning the benefits of cow’s milk and dairy in general. However, Michelle Routhenstein, preventive cardiology dietitian at Entirely Nourished, says that dairy does have several health benefits. “Pros for consuming dairy, particularly milk, include its nutrient-rich profile providing calcium, vitamin D, protein, potassium and other essential nutrients,” she tells Yahoo Life. Dairy has also been linked to a multitude of health benefits, including a reduced risk for type 2 diabetes and cardiovascular disease.

That said, you don’t need to consume it. “A well-planned, balanced diet that includes these nutrients in sufficient quantities can provide all the essential nutrients necessary for good health, without the need for dairy milk,” says Routhenstein. Lisa Andrews, dietitian and owner of Sound Bites Nutrition, agrees, telling Yahoo Life: “You don’t have to drink milk, and you shouldn’t if it causes gastrointestinal distress, allergic symptoms or you hate to drink it.”

Whether or not people actually need dairy — and milk in particular — there are still many myths and misperceptions that surround it. Yahoo Life asked dietitians to weigh in on the five most common misunderstandings about dairy that they encounter. Here’s what they have to say.

Is dairy harder to digest as you get older?

You’re not imagining things if that digestive discomfort after drinking milk seems to be getting worse as you age. This is likely due to lactose intolerance, a condition making it hard to digest lactose, a sugar found in dairy products.

Most newborns are able to produce lactase, an enzyme crucial for the digestion of lactose in the small intestine. However, after the infant weaning phase, most people start to have lower levels of lactase. In fact, about 36% of Americans and 68% of people in the world have lactose intolerance. The rest might have a special gene and are able to continue digesting milk into adulthood.

The good news: “You don’t have to completely eliminate dairy foods when you have lactose intolerance,” Amanda Sauceda, dietitian and founder of ​​the Mindful Gut, tells Yahoo Life. “Despite reduced lactase levels, many people can still tolerate some lactose in their diets, often in the form of yogurt and firm cheese, which have lower lactose due to processing. There’s also a variety of dairy foods low in lactose or lactose free, and lactase supplements that can aid in digestion of lactose-rich foods.”

Does dairy cause inflammation?

Routhenstein says this is a misconception that “stems from the fact that some individuals experience gastrointestinal discomfort or allergic reactions to dairy, leading to inflammation in certain cases.” While there’s some concern that the saturated fat found in full fat dairy, for example, can cause inflammation, it may be that it worsens inflammation that already exists instead.

Dairy in general contains many ingredients known to have anti-inflammatory properties, such as whey protein, antioxidants, probiotics and omega-3 fatty acids. A systematic review in 2020 of 27 randomized controlled studies backs this up and suggests that dairy products have a neutral to beneficial effect on inflammation. In particular, fermented dairy, like yogurt and kefir, are thought to create an anti-inflammatory environment and support gut health.

Is dairy good for bone health?

Dairy has long been thought to be necessary for bone health due to its high amounts of calcium — a key mineral in bones. “Research indicates that children and older adults who avoid or don’t consume dairy products are at higher risk for bone fracture,” says Andrews.

Many studies observed dairy positively affecting bone growth in children and adolescents, and bone turnover in adults. In addition to calcium, dairy’s high levels of protein and phosphates encourage bone growth. Specifically, fermented dairy products, like yogurt and kefir, which also provide probiotics, are associated with a lower risk of hip fracture. However, a 2019 systematic review and meta-analysis found mixed results linking dairy to a reduced risk of osteoporosis.

While dairy can support bone health, it’s not the determining factor. “Other factors such as genetics, physical activity and overall diet also play an important role in bone strength,” explains Routhenstein. And there are other good food sources for calcium besides dairy, including dark, leafy green vegetables like collard greens, spinach and kale, sardines and fortified orange juice.

Does milk help you sleep?

You may have heard that drinking a warm cup of milk before bed can help you sleep better. While it’s certainly cozy and soothing, research is mixed on whether this advice is accurate. Sauceda says that “dairy is a source of tryptophan, magnesium and zinc, which are all necessary for the production of melatonin,” a hormone that promotes sleep. Milk is also rich in calcium and vitamins A, D, and E, and research shows insufficient intake of these nutrients is associated with poor sleep.

How much milk you drink might matter. A U.K. study of 500,000 middle-aged adults found that an overall healthy diet with a moderate amount of milk was associated with good sleep, but too little or too much was associated with sleep problems and mental health issues. Generally, it’s recommended to have about 3 servings of dairy daily.

It’s important to note that many factors, like stress, physical activity, medical conditions and environment (including noise and room temperature), can also have an impact on your sleep. However, most studies suggest that, with a well-balanced diet, milk may contribute to improved sleep.

Is milk full of antibiotics?

It’s highly unlikely antibiotics will be found in your milk. The Food and Drug Administration’s pasteurized milk ordinance and each state follow strict regulations that do not allow milk with antibiotic residues to enter the food supply. A farmer might use antibiotics to treat a sick cow (this is also under constant scrutiny); however, the cow is then isolated, and their milk is discarded until all of the antibiotics are out of the cow’s system.

Milk is also tested when a tank arrives to pick up milk from a farm and when it arrives at a processing plant. If at any point a sample tests positive for antibiotics, the milk gets dumped, and action is taken against the farm.

Key takeaway

Experts agree that research about dairy is mixed in some cases, but overall, there’s potential for several different health benefits to consuming dairy products as part of a well-balanced diet.

Maxine Yeung is a dietitian and board-certified health and wellness coach.

Source

NYXI Unveils Revolutionary NYXI Warrior: The Ultimate Game-Changer for NGC Controllers

0

HONG KONG, March 5, 2024 /PRNewswire/ — Responding to gamer demands for an enhanced Switch controller experience and inspired by the Gamecube style, NYXI Wizard Series Joy-pad has taken the gaming community by storm. This idea was a brainchild of Michael, CEO of NYXI, who is tech-savvy, as well as being a nostalgia and gaming enthusiast. The success of the Wizard Series exemplifies NYXI unwavering commitment to delivering exceptional performance tailored to the gaming community’s preferences.

A Technological Leap Forward for NYXI

NYXI Warrior Bluetooth Controller (The nostalgic design and innovative technological features elevate it beyond any other Gamecube controllers in the market today. As the ultimate in NGC controllers, NYXI Warrior wireless controller stands out as the preferred option for nostalgic enthusiasts who want the best.)
NYXI Warrior Bluetooth Controller (The nostalgic design and innovative technological features elevate it beyond any other Gamecube controllers in the market today. As the ultimate in NGC controllers, NYXI Warrior wireless controller stands out as the preferred option for nostalgic enthusiasts who want the best.)

Fueled by the cutting-edge technology, NYXI is thrilled to unveil the latest innovation, the NYXI Warrior, which redefines NGC controllers with multi-platform compatibility and ultimate performance.

Brand-new Optical Microswitches

When milliseconds decide victory, NYXI’s optical microswitches in Warrior’s D-pad and A/B/X/Y ensure speed, precision, and durability. These switches feature instant activation, with 0.3mm actuation travel and 0.2ms response time—nearly three times faster than traditional mechanical switches. With up to 10 million clicks, NYXI’s optical microswitches offer lightning-fast precision crucial for competitive gaming, redefining gaming excellence.

Hall effect sensor technology for enhanced precision

NYXI Hall effect joysticks ensure no drift in lifetime. Additionally, NYXI also utilizes Hall effect sensors in the triggers to accurately measure changes in magnetic fields to ensure reliable game control. These sensors capture subtle movements, increasing accuracy in genres especially for racing games, FPS and other game genres that require fine manipulation.

Moreover, the NYXI Warrior controller features adjustable trigger lengths, granting gamers customization options for enhanced comfort during gameplay.

One Controller to Rule Them All

To elevate the gaming experience, along with HD rumble and an 8-way D-pad for precise directional control, NYXI have introduced interchangeable back paddles. This design allows gamers to freely choose programmable back buttons and activate turbo functions according to their personal preferences and gaming needs.

This customization feature enables gamers to seamlessly switch between e-sports and casual gaming with just one controller.

KEY FEATURES:

  • Compatibility: Switch (3.0.0 or above), Gamecube, Wii, Windows (Windows 10 or above)
  • Connectivity: Bluetooth, 2.4G Wireless Connection, USB-C Wired Connection
  • Hall Effect Joystick
  • Adjustable Hall Sensing Triggers
  • Interchangeable Back Paddle
    –freely choose programmable back buttons and turbo function.
  • Optical Microswitches A/B/X/Y & D-Pad
  • Mechanical L/R Buttons
  • HD RUMBLE
  • 6-Axis Gyroscope
  • 8-Way D-pad for Precise and Versatile Directional Control

The nostalgic design and innovative technological features elevate it beyond any other Gamecube controllers in the market today. As the ultimate in NGC controllers, NYXI Warrior stands out as the preferred option for nostalgic enthusiasts who want the best.

Pre-orders for the NYXI Warrior start on March 5th. Visit the website for more information: NYXIGAME.COM

Source

1 in 8 people worldwide are now obese. How is obesity measured?

0

On March 1, the World Health Organization (WHO) reported findings from a recent Lancet study that revealed 1 in 8 people worldwide are now living with obesity. More specifically, the latest data reveals that, in 2022, 2.5 billion adults (or 43%) were overweight; of those, 890 million adults were living with obesity — a figure that’s more than doubled since 1990. Adolescent obesity has quadrupled since 1990, with 160 million 5- to 19-year-olds considered obese.

But what’s the difference between being overweight and being obese? And as the WHO report renews calls to help prevent and manage obesity on a global scale, what are some interventions that can help? Here’s what to know.

Obesity vs. overweight

Obesity is “a chronic relapsing disease characterized by excess deposits of fat that can impair health,” says Dr. Francesco Branca, director of the department of nutrition and food safety in the WHO. More simply, he tells Yahoo Life that it’s “a more severe form of overweight.” The differentiating factors are the health risks that obesity is associated with.

According to the WHO, obesity leads to higher risk of:

  • Cardiovascular disease

  • Type 2 diabetes

  • Kidney disease

  • Certain cancers

  • Issues with bone health

  • Reproductive health issues

  • Impaired daily functions, such as moving and sleeping

Branca says that comorbidities of obesity — which include health conditions such as diabetes, hypertension and obstructive sleep apnea — account for about 5 million deaths globally every year.

Overweight, on the other hand, isn’t correlated with any “reliable increased risk of morbidity and mortality,” Dr. Melanie Jay, director of NYU Langone’s Comprehensive Program on Obesity, tells Yahoo Life. “But we know that when someone is in the quote unquote overweight range, they have higher risk of developing obesity in the future,” as a result of natural weight gain patterns.

Each condition is defined by body mass index, which is said to measure body fat based on a person’s height and weight. Although the measurement tool is controversial, it is used as a screening method for weight categories such as:

Jay says BMI is “useful on a population level” for the sake of predicting levels of adipose tissue and fat, and therefore, rates of obesity. On an individual level, however, there are more metrics of health that need to be taken into account. For example, blood sugar levels, cholesterol and other factors are among the things that Jay looks for in her own patients. Other physical measurements, such as waist circumference, are also taken into account. “There are people who have higher body mass index that would be considered higher risk, but they individually are not because they are not having the same co-morbidities or complications at that BMI,” she says.

On the flip side, “You can have people in the overweight range who still have a lot of visceral fat, a lot of weight gain in their abdomen, who have a family history of diabetes, who might have pre-diabetes or diabetes. So that’s more important than their BMI at that point.” She adds that the measure alone “is not a good indication of health.”

Social determinants of health — defined by the Centers for Disease Control and Prevention (CDC) as “non-medical factors that influence health outcomes,” such as the conditions under which people live and work, along with racism and climate change — also play a role in the likelihood of having obesity versus being overweight.

What causes or contributes to obesity?

Branca says that the disease results from “an energy imbalance, generated by unhealthy dietary intakes and inadequate levels of physical activity.” And while weight bias contributes to the belief that obesity is a result of personal responsibility, experts say there’s very little of that playing a role in a person’s diagnosis.

“Obesity is always an interaction of genetic predisposition and the environment that someone is living in, including the people they interact with and the food that’s available. And then there are medications and other things that increase the risk of obesity and cause people to gain weight,” explains Jay. “Most of obesity has nothing to do with personal choices.”

A spokesperson for the division of nutrition, physical activity and obesity at the CDC agrees, telling Yahoo Life: “Neighborhood design, access to nutritious, affordable foods and beverages and access to safe and convenient places for physical activity can all impact weight and health. The racial and ethnic disparities in obesity underscore the need to address factors that influence health and remove barriers to it, such as poverty, education and housing.”

This is why Jay says that obesity prevention requires high-level interventions. “That means structuring society so that healthier choices are automatic and easier, addressing our global food supply to have healthier choices and enough fruits and vegetables, and having built environments with opportunities for people to walk more and to do more physical activity safely.”

The bottom line, says Jay, is that “there are things that we know are fueling this global surge of obesity rates and then I think there’s still a lot of things we don’t know.” And because prevention is important in decreasing rates of obesity, experts say more attention needs to be paid to policies and their impact.

What does treatment look like?

“Treatment of obesity requires an integrated approach, including long-term support of lifestyle changes provided by a well-trained team of health practitioners — doctors, dietitians, psychologists — possibly accompanied by pharmacological and/or surgical treatment, depending on the severity of the condition,” explains Branca.

Jay says that “we’ve all heard about the newer injectable medications. But there’s also several medications that have been around longer, that are less expensive and might be more available at this moment.” But, she points out, “we have 1 billion people” living with obesity. “We want to prevent it,” she says. “We do need a lot more research and to be trying a lot more things when it comes to obesity prevention or even preventing further increases in the rates of obesity.”

Source

How to watch the Oscars: Where to stream live without cable, full nominee list and more

0

It’s almost time for the 96th Academy Awards! On Sunday, Mar. 10, Hollywood’s biggest names of the year will gather at the Dolby Theatre in Los Angeles, California to hand out those coveted gold statues. This year, Christopher Nolan’s epic biopic Oppenheimer leads in nominations with a whopping 13 nods, Yorgos Lanthimos’ quirky comedy Poor Things is in second place with 11 nods and Martin Scorsese’s Killers of the Flower Moon takes third with 10. Greta Gerwig’s box office record-breaker Barbie earned eight nominations, including for Best Picture, but both Gerwig and the film’s lead actress and producer, Margot Robbie, were notably not nominated in their respective categories.

The Oscars will see performances of all five of the original songs nominated this year, including a much-anticipated live performance of “I’m Just Ken” from Ryan Gosling. The awards show will also have a star-studded slate of presenters, which includes Zendaya, Nicolas Cage, Jamie Lee Curtis, Brendan Fraser, Matthew McConaughey, Michelle Yeoh and Al Pacino.

Are you ready to tune in? Here’s what you need to know about watching the 2024 Oscars this year — with or without cable.

P.S. — looking for where to watch all the Oscars Best Picture nominees? We’ve got you covered there too.

When are the 2024 Oscars?

The Oscars will be held on Sunday, Mar. 10.

What time are the Oscars on?

This year, the Oscars will start an hour earlier than usual, beginning at 7 p.m. ET.

What channel are the Oscars on?

The 96th Academy Awards will air on ABC, which you may have access to through cable or a live TV antenna. Don’t have access to ABC? You can stream the channel live with the help of a live TV streaming service like Fubo, Sling, DirecTV Stream and more, or grab yourself an old school TV antenna to tune into ABC free (as long as you live in an area with good enough over-the-air service). Here’s what we recommend for how to watch the Academy Awards without cable.

How to watch the Oscars:

  • Channel Master Flatenna Ultra-Thin Indoor TV Antenna 35 Mile Range – Dual Sided Black or White – CM-4001HDBW

    Watch local ABC (in eligible areas)

Where to stream the Oscars:

Who is hosting the 2024 Oscars?

Jimmy Kimmel will once again host the Academy Awards this year.

Who is performing at the Oscars this year?

FILE - Ryan Gosling arrives at the 96th Academy Awards Oscar nominees luncheon on Monday, Feb. 12, 2024, at the Beverly Hilton Hotel in Beverly Hills, Calif. Gosling will sing the pop power ballad “I’m Just Ken” at the Oscars on March 10. (Photo by Jordan Strauss/Invision/AP, File)

Ryan Gosling will perform “I’m Just Ken” at the Oscars this year. (Jordan Strauss/Invision/AP, File)

All five of this year’s Academy Award-nominated original songs will be performed at the Oscars this year. Jon Batiste, Becky G, Billie Eilish and Finneas O’Connell, Scott George and the Osage Singers, and — finally confirmed — Ryan Gosling and Mark Ronson.

Who is presenting at the 2024 Oscars?

So far, the list of confirmed Oscars presenters includes Zendaya, Nicolas Cage, Jamie Lee Curtis, Brendan Fraser, Matthew McConaughey, Michelle Yeoh, Al Pacino, Michelle Pfeiffer, Mahershala Ali, Jessica Lange, Ke Huy Quan, Bad Bunny, Chris Hemsworth, Dwayne Johnson, Michael Keaton, Regina King, Jennifer Lawrence, Kate McKinnon, Rita Moreno, John Mulaney, Catherine O’Hara, Octavia Spencer, Ramy Youssef and Sam Rockwell.

2024 Oscar nominees:

Best supporting actor

Sterling K. Brown, “American Fiction”

Robert De Niro, “Killers of the Flower Moon”

Robert Downey Jr., “Oppenheimer”

Ryan Gosling, “Barbie”

Mark Ruffalo, “Poor Things”

Best costume design

“Barbie” – Jacqueline Durran

“Killers of the Flower Moon” – Jacqueline West

“Napoleon” – David Crossman, Janty Yates

“Oppenheimer” – Ellen Mirojnick

“Poor Things” – Holly Waddington

Best makeup and hairstyling

“Golda”

“Maestro”

“Oppenheimer”

“Poor Things”

“Society of the Snow”

Best live action short film

“The After”

“Invincible”

“Knight of Fortune”

“Red, White and Blue”

“The Wonderful Story of Henry Sugar”

Best animated short film

“Letter to a Pig”

“Ninety-Five Senses”

“Our Uniform”

“Pachyderme”

“War Is Over! Inspired by the Music of John & Yoko”

Best adapted screenplay

“American Fiction” – Cord Jefferson

“Barbie” – Noah Baumbach, Greta Gerwig

“Oppenheimer” – Christopher Nolan

“Poor Things” – Tony McNamara

“The Zone of Interest” – Jonathan Glazer

Best original screenplay

“Anatomy of a Fall” – Justine Triet, Arthur Harari

“The Holdovers” – David Hemingson

“Maestro” – Bradley Cooper, Josh Singer

“May December” – Samy Burch, Alex Mechanik

“Past Lives” – Celine Song

Best supporting actress

Emily Blunt, “Oppenheimer”

Danielle Brooks, “The Color Purple”

America Ferrera, “Barbie”

Jodie Foster, “Nyad”

Da’Vine Joy Randolph, “The Holdovers”

Best original song

“The Fire Inside” from “Flamin’ Hot”

“I’m Just Ken” from “Barbie”

“It Never Went Away” from “American Symphony”

“Wahzhazhe (A Song For My People)” from “Killers of the Flower Moon”

“What Was I Made For?” from “Barbie”

Best original score

“American Fiction”

“Indiana Jones and the Dial of Destiny”

“Killers of the Flower Moon”

“Oppenheimer”

“Poor Things”

Best documentary feature film

“Bobi Wine: The People’s President”

“The Eternal Memory”

“Four Daughters”

“To Kill a Tiger”

“20 Days in Mariupol”

Best documentary short film

“The ABCs of Book Banning”

“The Barber of Little Rock”

“Island In Between”

“The Last Repair Shop”

“Nǎi Nai & Wài Pó”

Best international feature film

“Io Capitano” (Italy)

“Perfect Days” (Japan)

“Society of the Snow” (Spain)

“The Teachers’ Lounge” (Germany)

“The Zone of Interest” (United Kingdom)

Best animated feature film

“The Boy and the Heron”

“Elemental”

“Nimona”

“Robot Dreams”

“Spider-Man: Across the Spider-Verse”

Best production design

“Barbie”

“Killers of the Flower Moon”

“Napoleon”

“Oppenheimer”

“Poor Things”

Best film editing

“Anatomy of a Fall”

“The Holdovers”

“Killers of the Flower Moon”

“Oppenheimer”

“Poor Things”

Best sound

“The Creator”

“Maestro”

“Mission: Impossible – Dead Reckoning Part One”

“Oppenheimer”

“The Zone of Interest”

Best visual effects

“The Creator”

“Godzilla Minus One”

“Guardians of the Galaxy Vol. 3”

“Mission: Impossible – Dead Reckoning Part One”

“Napoleon”

Best cinematography

“El Conde” – Edward Lachman

“Killers of the Flower Moon” – Rodrigo Prieto

“Maestro” – Matthew Libatique

“Oppenheimer” – Hoyte van Hoytema

“Poor Things” – Robbie Ryan

Best actor

Bradley Cooper, “Maestro”

Colman Domingo, “Rustin”

Paul Giamatti, “The Holdovers”

Cillian Murphy, “Oppenheimer”

Jeffrey Wright, “American Fiction”

Best actress

Annette Bening, “Nyad”

Lily Gladstone, “Killers of the Flower Moon”

Sandra Hüller, “Anatomy of a Fall”

Carey Mulligan, “Maestro”

Emma Stone, “Poor Things”

Best director

Justine Triet, “Anatomy of a Fall”

Martin Scorsese, “Killers of the Flower Moon”

Christopher Nolan, “Oppenheimer”

Yorgos Lanthimos, “Poor Things”

Jonathan Glazer, “The Zone of Interest”

Best picture

“American Fiction”

“Anatomy of a Fall”

“Barbie”

“The Holdovers”

“Killers of the Flower Moon”

“Maestro”

“Oppenheimer”

“Past Lives”

“Poor Things”

“The Zone of Interest”

More ways to watch ABC without cable:

Source

Hybribio Calls for Raising International HPV Awareness

0

GUANGZHOU, China, March 4, 2024 /PRNewswire/ — March 4th 2024 marks the 7th International HPV Awareness Day, a global campaign proposed by the International Papillomavirus Society (IPVS) since 2018. This year, the theme is One Less Worry. On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Hybribio Cervical Cancer HPV Primary Screening Solution
Hybribio Cervical Cancer HPV Primary Screening Solution

According to the World Health Organization (WHO), there is an estimated amount of 625,600 women and 69,400 men suffering from HPV-related cancers each year. Persistent HPV infection with high-risk HPV types is the predominant cause of cervical cancer and also has a close association with other types of cancers including oropharyngeal, anal, vulvar, vagina, and penile cancers. In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.

In 2020, the World Health Assembly adopted a global strategy to accelerate the elimination of cervical cancer. Additionally, on the path towards cervical cancer elimination, WHO raised a 90-70-90 target that must be met by all countries by 2030, which states that 70% of women should receive at least one HPV molecular test by the age of 35, and another one by 45. As the pioneer and advocator of HPV DNA testing in China, Hybribio has been promoting HPV DNA testing as the primary screening for cervical cancer and participating in women’s cervical cancer screening programs both in urban and rural areas since 2007. From 2009-2011, Hybribio organized over 600 training sessions for clinicians domestically to raise public awareness of HPV infection, screening and treatment. As of March 2024, Hybribio has provided over 67 million HPV DNA tests for females, ultimately safeguarding countless lives.

Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit. In June 2023, Hybribio 14 High-risk HPV with 16/18 Genotyping Real-time PCR kit obtained the firstly approved NMPA cervical cancer primary screening license, marking a milestone of high-performance and high-standard HPV DNA testing for cervical cancer primary screening in China. With Hybribio Fully Automated Sample Preparation Liquid Handling System HB-IEX96A and commercial general Real-time PCR system, it can achieve highly efficient large-scale cervical cancer primary screening.

In addition to HPV diagnostic reagents, Hybribio has been working on HPV-related medication. The Hybribio chloroquine gel (in development) has been awarded multiple invention patents in countries (e.g. U.S.A., Russia, Japan), which is intended for the treatment of low-risk HPV infections, including skin warts such as metatarsal warts, flat warts, genital warts and perianal condyloma acuminatum, etc.

Raising international HPV awareness is the very first step against cervical cancer. It requires the participation of different parties from hospitals, enterprises, organizations, and government authorities to all women individuals. Hybribio endeavors to provide cutting-edge HPV diagnostic solutions and is committed to eliminating cervical cancer. Get vaccination, get screening, get treatment. Together we can triumph HPV!

About Hybribio

Founded in 2003, Hybribio (300639.SZ) is a leading nucleic acid test supplier and manufacturer who specializes in in-vitro diagnostic products with a fully integrated one-step operation chain from R&D, manufacturing, and sales & marketing to after-sales technical support services. Hybribio provides products including, but not limited to, women’s health, reproductive health, genetic diseases, methylation, respiratory tract infection, pharmacogenetics and instrumentation.

For more information, please visit: www.hybribio.com

Source: Guangdong Hybribio Biotech Co.,Ltd.

Source